PETRI DISH PERSPECTIVES

September 2026: Biotech & Pharma NEWS Roundup

Описание

Send us Fan Mail

Welcome to your essential overview of the global biotech and pharmaceutical landscape for September 2026!

This month was defined by blockbuster dealmaking, historic FDA approvals, and a growing recognition that pharmaceutical innovation is shifting east. AstraZeneca made a $2 billion strategic bet on Summit Therapeutics and its ivonescimab program, Novo Nordisk paid up to $2.6 billion for a once-weekly oral GLP-1 from China's Hengrui, and Eli Lilly continued its relentless dealmaking streak with a $3.25 billion InnoCare partnership. On the regulatory front, the FDA approved the first-ever treatment for Sanfilippo syndrome, a first-in-class Parkinson's drug, the world's first radioligand equivalent, and a new once-weekly insulin, a remarkable month for patients with rare and chronic diseases. ADARx raised $446 million in one of biotech's largest IPOs of the year, and Electra Therapeutics upsized its own raise to $350 million, signaling that the IPO window remains open for the right science. Meanwhile, Novo's total workforce cuts reached 13,000 and BMS continued trimming headcount, a reminder that even the industry's biggest players are restructuring for what comes next. The bigger story is unmistakable: China is no longer just manufacturing drugs for the West, it is discovering them, and the deals signed this month prove that Big Pharma has fully accepted that reality.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes!

https://linktr.ee/maneadkhin

#PetriDishPerspectives #BiotechNews #PharmaNews

Support the show

© 2026 The Perspective Bureau LLC. All rights reserved.

Комментарии

Комментариев пока нет — напишите первый.